Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Summary

This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).

Timeline

Start

2023-12-11

Primary completion

2025-05-28

Completion

2025-05-28

Outcome

Outcome not reported

Stopped (Business): “Lack of Funding”

Publications

• Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS. A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT. Blood. 2026 Apr 23;147(17):1914-1927. doi: 10.1182/blood.2025031053.

Drugs

Indications